In cervical cancer, CD74 expression in tumor-associated macrophages (TAM) was shown to modulate response to therapy; CD74 blockade augmented the efficacy of neoadjuvant chemotherapy when combined with PD-1 checkpoint inhibition, implicating CD74 as a therapeutic co-target [73]. This evidence concerns the gene CD74 and cervical cancer.